Abacavir Sulfate: CAS Registry Number 188062-50-2
Wiki Article
Abacavir sulfate, chemically defined as registration number 188062-50-2, is a potent HIV medication. It suppresses the proliferation of the human immunodeficiency virus (HIV) by interfering with the viral enzyme reverse transcriptase. This enzyme is crucial in the HIV life cycle, allowing the virus to integrate its genetic material into the host's DNA. Abacavir sulfate frequently administered in combination with other antiretroviral drugs as part of a comprehensive treatment regimen for HIV infection.
Abarelix : Chemical Identifier 183552-38-7
Abarelix, also known by its chemical identifier 183552-38-7, is a/represents/serves as a gonadotropin-releasing hormone (GnRH) antagonist. It functions by/operates through/acts upon blocking the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. This ultimately reduces/suppresses/minimizes testosterone production in men, making it a valuable treatment option for prostate cancer. Abarelix is typically administered/delivered/infused as an injection, usually on a monthly basis.
Abiraterone Acetate: CAS Registry Number 154229-18-2
Abiraterone acetate plays a role the medication employed in ALPHA LIPOIC ACID 1077-28-7 the management of prostate cancer. It substance acts by suppressing an protein known as 17-alpha-hydroxylase/17,20-lyase, which then stops the synthesis of androgens, male held accountable for fueling prostate cancer growth. CAS Registry Number 154229-18-2 represents the unique code of abiraterone acetate, confirming its accurate identification within medical communities.
Examination of Abacavir Sulfate's Chemical Properties
Abacavir sulfate, with the chemical identifier CAS 188062-50-2, acts as a vital component in the treatment of HIV infection. This potent antiretroviral agent effectively inhibits the replication of the human immunodeficiency virus (HIV). Abacavir sulfate falls under the class of nucleoside reverse transcriptase inhibitors (NRTIs).
Its chemical structure consists of a complex arrangement of molecules. The molecule presents characteristic attributes that contribute to its biological activity and therapeutic efficacy.
Comprehending the chemical profile of abacavir sulfate provides valuable insights into its mechanism of action, pharmacokinetics, and potential outcomes with other agents.
Pharmaceutical Compound Identification: Abaarelix (CAS 183552-38-7)
Abaarelix, identified by the CAS registry number 183552-38-7, represents a significant pharmaceutical compound within the realm of medicine. Its primary functionality revolves around the manipulation of hormone levels, particularly targeting gonadotropin-releasing hormone (GnRH). This specific mechanism makes Abaarelix relevant in the control of various conditions, notably those involving androgen-dependent growth or proliferation.
- Studies into Abaarelix have revealed its efficacy in ameliorating symptoms associated with prostate cancer, endometriosis, and certain types of infertility.
- Additionally, the compound's absorption properties have been extensively evaluated to confirm its safety and compliance in clinical settings.
Consequently, Abaarelix has emerged as a significant therapeutic strategy in the modern medical landscape, offering hope and improved well-being to patients grappling with these challenging conditions.
Structure and Properties of Abiraterone Acetate CAS No. 154229-18-2
Abiraterone acetate, identified by the chemical designation CAS No. 154229-18-2, is a potent synthetic molecule. It exhibits a complex arrangement characterized by a copyright skeleton. This structure encompasses multiple functional groups, contributing to its therapeutic properties.
Abiraterone acetate is a non-copyrightal inhibitor of the enzyme 17α-hydroxylase/lyase (CYP17A1), which plays a crucial role in the synthesis of androgens, primarily testosterone. By effectively inhibiting CYP17A1, abiraterone acetate decreases androgen production within the body, thus offering potential therapeutic benefits in the management of prostate cancer.
Report this wiki page